Prerna Mewawalla, MD

Caution remains necessary when applying ENDURANCE trial findings to high-risk disease, explains Prerna Mewawalla, MD.

Recent ENDURANCE data support 2-year lenalidomide maintenance in standard-risk multiple myeloma and individualize when to stop.

She frames the IberDd approval as more than the addition of 1 more regimen to a crowded relapsed/refractory myeloma armamentarium.

The myeloma space has undergone tremendous transformation recently, says Prerna Mewawalla, MD, including CAR T-cell therapies and bispecific antibodies.

Bispecific antibodies are delivering unprecedented response rates in multiple myeloma, offering fast, flexible options alongside CAR T-cell therapy, explains Prerna Mewawalla, MD.

Prerna Mewawalla, MD, discusses innovative strategies to enhance cancer care access, reduce clinician burden, and improve clinical trial diversity in real-world settings.